Oral presentations

BSG plenary

OC-001 THE IMPACT OF THE INTRODUCTION OF FORMALISED POLYPECTOMY ASSESSMENT ON TRAINING IN THE UNITED KINGDOM

doi:10.1136/gutjnl-2013-304907.001

¹K Patel, ¹O Faiz, ²M D Rutter, ³P Dunckley, ¹S Thomas-Gibson. ¹Wolfson Unit for Endoscopy, St Mark's Hospital, London; ²Department of Gastroenterology, University Hospital of North Tees, Stockton-on-Tees; ³Department of Gastroenterology, Gloucestershire Royal Hospital, Gloucester, UK

Introduction Polypectomy is regarded as the most hazardous part of colonoscopy, accounting for the majority of procedure-associated morbidity and yet is a necessary skill for all colonoscopists. Training in polypectomy has, to date, been variable and poorly structured. Anecdotal evidence suggested poor exposure to polypectomy during training. A novel assessment tool, the Directly Observed Polypectomy Skills (DoPYS), was introduced nationally in the United Kingdom in October 2011 with the intention of both improving training and facilitating documentation of competency.

Methods The aim was to assess the impact of the mandatory introduction of the DoPYS as part of the formal colonoscopy certification process. Applications for certification in the year prior to the introduction of DoPYS were analysed retrospectively and compared with data collected prospectively for those in the following year.

Data were collected on the total lifetime number of colonoscopies performed, the number of assessments for both colonoscopy and polypectomy and whether applicants had any evidence of performing polypectomy before certification of competence in colonoscopy.

Results There were 175 applicants for certification in the first year. The median number of procedures per candidate was 287. Thirty two per cent of candidates had evidence of any observed polypectomy with 7 per cent of candidates referring to training in endoscopic mucosal resection (EMR). The median number of formative colonoscopy assessments was 3 (range 0–16).

In the year since DoPYS was introduced there were 150 applications for certification. The median number of procedures per candidate was 206. All of these candidates had evidence of polypectomy assessment with a median number of DoPYS of 7 (range 3–27). 89 per cent of applicants had evidence of assessed EMR. The median number of formative colonoscopy assessments in this cohort was 32 (range 9–199).

There was a significant increase in the number of logged polypectomy assessments ($p < 0.001$), experience of EMR ($p < 0.001$) and formative colonoscopy assessments ($p < 0.001$). There was no significant difference in the total number of colonoscopy procedures performed.

Conclusion These data – the largest in the literature to date – show that structured polypectomy assessment improves trainees' documented exposure to therapeutic endoscopy as well as providing formal evidence of skills acquisition. As polypectomy plays an increasing role globally in colorectal cancer prevention, the DoPYS provides an effective means of assessing and certifying polypectomy in order to minimise the well-recognised risks associated with this technique.

Disclosure of Interest None Declared.

OC-002 SELECTIVE ALPHA V INTEGRIN DELETION IDENTIFIES A CORE, TARGETABLE MOLECULAR PATHWAY THAT REGULATES FIBROSIS ACROSS SOLID ORGANS

doi:10.1136/gutjnl-2013-304907.002

¹N Henderson, ²T Arnold, ³Y Katamura, ⁴M Giacomini, ⁵J Rodriguez, ⁶J McCarty, ⁴P Ruminski, ⁴D Griggs, ⁵J Maher, ¹J Iredale, ⁶A Lacy-Hulbert, ⁷R Adams, ²D Sheppard. ¹MRC Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK; ²Lung Biology Center, UCSF, San Francisco; ³Dept of Cancer Biology, University of Texas MD Anderson Cancer Centre, Houston; ⁴St Louis University, St Louis; ⁵The Liver Centre, UCSF, San Francisco; ⁶Harvard Medical School, Boston, United States; ⁷Dept of Tissue Morphogenesis, University of Munster, Munster, Germany

Introduction Myofibroblasts are the major source of extracellular matrix components that accumulate during tissue fibrosis, and hepatic stellate cells (HSCs) are the major source of myofibroblasts in the liver. To date, robust systems to genetically manipulate these cells have not existed. The paucity of tools that allow reliable, specific inactivation of genes in myofibroblasts *in vivo* has greatly hindered progress in understanding the underlying biology of fibrotic diseases.

Methods Mouse models of organ fibrosis: Chronic carbon tetrachloride injection (liver fibrosis), intratracheal bleomycin instillation (lung fibrosis) and unilateral ureteric obstruction (kidney fibrosis). Fluorescent reporter mice: mTmG (Td tomato/EGFP) and Ai14 (Rosa-CAG-LSL-TdTomato-WPRE) mice were crossed with *PDGFRβ* (platelet derived growth factor beta)-Cre mice. Integrin knock-out mice: *Itgav^{fllox/fllox}*, *itgb8^{fllox/fllox}* and *Itgb6^{-/-}* mice were maintained on C57BL/6 background and *itgb3^{-/-}* and *Itgb5^{-/-}* mice were maintained on a 129/svJae background. Fluorescent cell sorting: Td Tomato positive cells from Ai14; *PDGFRβ*-Cre mice were sorted using a FACSAria.

Results We report that *PDGFRβ* (platelet derived growth factor receptor beta) Cre inactivates genes in murine HSCs with high efficiency. We used this system to delete the integrin αv subunit because of the suggested role of multiple αv integrins as central mediators of fibrosis in multiple organs. Deletion of the αv integrin subunit in HSCs protected mice from CCl₄-induced hepatic fibrosis, whereas global loss of $\alpha v\beta 3$, $\alpha v\beta 5$ or $\alpha v\beta 6$ or conditional loss of $\alpha v\beta 8$ on HSCs did not. *PDGFRβ*-Cre effectively targeted myofibroblasts in multiple organs, and deletion of αv integrins using this system was also protective in bleomycin-induced pulmonary fibrosis and renal fibrosis induced by unilateral ureteric obstruction. Critically, pharmacological blockade of αv integrins by a novel small molecule (CWHM 12) attenuated both liver and lung fibrosis, even when administered after fibrosis was established.

Conclusion These data identify a core cellular and molecular pathway that regulates fibrosis, and suggest that pharmacological targeting of all αv integrins may have clinical utility in the treatment of patients with a broad range of fibrotic diseases.

Disclosure of Interest N. Henderson: None Declared, T. Arnold: None Declared, Y. Katamura: None Declared, M. Giacomini: None Declared, J. Rodriguez: None Declared, J. McCarty: None Declared, P. Ruminski Shareholder of: Antegrin Therapeutics, LLC., D. Griggs Shareholder of: Antegrin Therapeutics, LLC., J. Maher: None Declared, J. Iredale: None Declared, A. Lacy-Hulbert: None Declared, R. Adams: None Declared, D. Sheppard: None Declared.

Liver free papers

OC-003 MULTICENTRE RANDOMISED CONTROLLED STUDY COMPARING CARVEDILOL WITH ENDOSCOPIC BAND LIGATION IN THE PREVENTION OF VARICEAL REBLEEDING

doi:10.1136/gutjnl-2013-304907.003

¹L A Smith, ¹S Dickson, ²P C Hayes, ³D Tripathi, ²J W Ferguson, ¹E H Forrest, ¹D R Gaya, ³P R Mills, ⁴H Suzuki, ⁵D Young, ¹A J Stanley. ¹Gastroenterology, Glasgow Royal Infirmary, Glasgow; ²Liver Unit, Royal Infirmary of Edinburgh, Edinburgh; ³Gastroenterology, Gartnavel General Hospital; ⁴Gastroenterology, Southern General Hospital; ⁵Biostatistics, University of Strathclyde, Glasgow, UK

Introduction Rebleeding after an initial oesophageal variceal haemorrhage remains a significant problem despite therapy with

band ligation $\pm$ non-selective β -blockers. Carvedilol is a vasodilating non-selective β -blocker with α -1 receptor and calcium channel antagonism. It has a greater portal hypotensive effect than propranolol and has been shown to be effective in the prevention of a first variceal bleed. Our aim was to compare oral carvedilol with band ligation in the prevention of rebleeding following a first variceal bleed.

Methods Patients who were stable 5 days after presentation with a first variceal haemorrhage and had not been taking (or had contraindications to) β -blockers, were randomised to oral carvedilol (6.25 mg daily then 12.5 mg daily after one week if tolerated) or a band ligation programme. Patients were followed up at clinic after one week, monthly, then 3-monthly. The primary end-point was variceal rebleeding, on intention-to-treat analysis.

Results 63 patients were randomised, 32 to carvedilol and 31 to banding. Fifty-six (89%) patients had alcohol related liver disease. There was no difference in baseline mean age (51 yrs $\pm$ 10.9 and 50 yrs $\pm$ 13.0) or median Childs Pugh score (9, IQR 6–11 and 9, IQR 8–11) for patients randomised to carvedilol or banding respectively. Mean follow-up was 29 months. Compliance was 72% and 90% for carvedilol and banding respectively ($p = 0.14$) and there was no difference in the number of serious adverse events between the two groups. Variceal rebleeding occurred during follow-up in 12 (37.5%) and 9 (29.0%) patients in the carvedilol and banding groups respectively ($p = 0.72$), with mortality 25.0% and 51.6% respectively ($p = 0.058$). The differences in outcome between groups were similar using per protocol analysis. This interim analysis indicates that to show a significant difference in rebleeding, 482 patients would be required in each group.

Conclusion Carvedilol is not clearly superior to band ligation in the prevention of variceal rebleeding. However there appears to be a survival benefit for patients taking this drug compared with those undergoing banding, which requires further exploration.

Disclosure of Interest None Declared

OC-004 IN VITRO STEROID SENSITIVITY ACCURATELY PREDICTS 6 MONTH MORTALITY IN PATIENTS WITH SEVERE ALCOHOLIC HEPATITIS

doi:10.1136/gutjnl-2013-304907.004

^{1,2}A Dhand, ³A Di Mambro, ²A McCune, ²F Gordon, ²J Portal, ²P Collins. ¹School of Clinical Sciences, University of Bristol; ²Department of Liver Medicine, University Hospitals Bristol NHS Foundation Trust, Bristol; ³Department of Gastroenterology, Weston General Hospital, Weston-super-mare, UK

Introduction Severe alcoholic hepatitis (SAH) has a high mortality especially in those who fail to respond to steroid treatment. Early identification of steroid resistant patients may allow rapid implementation of other therapies, which may improve patient outcome. An early change in bilirubin has prognostic value but requires 7 days of steroid treatment first. Our group have previously reported that a simple 48h *in vitro* method for assessing steroid sensitivity (dexamethasone inhibition of lymphocyte proliferation; DILPA) correlates with 6 month mortality in patients with SAH[1]. We aimed to determine the accuracy of the DILPA in predicting outcome and to compare it to existing models of prognosis in SAH.

Methods Peripheral blood was drawn from consecutive patients with a clinical diagnosis of SAH (Maddrey discriminant function [MDF] > 32). All subjects gave informed consent and ethical approval was obtained from the regional ethics committee. The primary outcome measure was 6 month mortality. Leukocytes, isolated by density gradient centrifugation, were cultured for 48h with the mitogen PHA in the presence or absence of dexamethasone. Tritiated thymidine was added for the final 6h of culture before proliferation was measured on a beta counter. Maximum suppression of lymphocyte proliferation by dexamethasone was calculated (Imax).

An Imax of $< 60\%$ indicates *in vitro* steroid resistance as previously determined. The accuracy of the DILPA and existing scoring systems (MDF, MELD, Glasgow and Lille scores) was calculated by area under the receiver operating characteristic (AUROC). Logistic regression of baseline and day 7 parameters was performed to determine independent predictors of outcome.

Results 43 patients were recruited (21% female, median age 45). Patients who survived 6 months had a significantly higher Imax than those who didn't (79.2% v 41.7%; $p = 0.0003$). An Imax of $> 60\%$ had a 88% sensitivity and 78% specificity in predicting 6 month survival and an AUROC of 0.83. MDF, MELD, Glasgow and Lille scores all had lower AUROC values for predicting 6 months survival than Imax (0.36, 0.4, 0.49 and 0.61 respectively). A stepwise logistic regression demonstrated that only Imax, Day 0 albumin and change in bilirubin at Day 7 of treatment were independent predictors of 6 month survival.

Conclusion The DILPA provides a simple, fast and accurate *in vitro* method of predicting clinical outcome in patients with SAH. This could be applied in clinical practise to identify patients who will not respond to steroid therapy within 2 days of starting treatment.

Disclosure of Interest None Declared

REFERENCE

1. Di Mambro *et al.* Hepatology 2011;53:1316–22.

OC-005 THE EARLY EXPANSION OF INTRAHEPATIC NK CELLS IS ASSOCIATED WITH CLEARANCE OF HCV AFTER IFN-ALPHA -BASED TREATMENT

doi:10.1136/gutjnl-2013-304907.005

¹T Pembroke, ¹A Gallimore, ¹A Godkin. ¹School of Medicine, Cardiff University, Cardiff, UK

Introduction Chronic hepatitis C virus (HCV) infection is a major cause of liver failure, cirrhosis and hepatocellular carcinoma. Current treatments are evolving but still largely rely on IFN α in combination with ribavirin +/- protease inhibitors. IFN α can activate Natural killer (NK) cells: large granular lymphocytes that can target virally-infected cells. NK cells may play a role in the immune response to chronic HCV. We examined whether the kinetics of NK cell expansion and activation affected long-term treatment success.

Methods Repeated matched blood and intrahepatic (IH) NK cells were obtained from 9 patients before treatment and on days 1, 3, 7, 14, 28 and 86 of treatment. IH samples were obtained by fine needle aspirations. NK cell phenotype (CD16, NKp30, NKp46 & NKG2D) and functional markers (CD107a, IFN γ & granzyme B) were assessed by flow cytometry. Rate of viral clearance (k) was calculated from serial serum viral loads during treatment.

Results Multiple IH samples were obtained from 9 subjects. 5 of the 9 patients achieved viral clearance i.e. SVR; 4 failed treatment. The proportion of IH lymphocytes that were NK cells increased from mean 10% (+/-0.97% SEM) at baseline to 16.1% (+/-2.43% SEM) after 24 hours ($p = 0.021$) and 17.9% (+/-4.75% SEM) after 72 hours ($p = 0.023$). The proportions returned to baseline levels from day 7 onwards. The proportion of IH NK cells was greater in patients who achieved SVR (18.6%) than those who failed treatment (11.9%). The rate of viral clearance correlates with IH NK cells at day 1 ($p = 0.036$). IH NK cells at 24 hours demonstrated an increase in activation i.e. increase CD107a externalisation, decreased granzyme B and CD16 expression.

Conclusion IH NK cells are cytotoxically active during the early phase of treatment when reduction in viral load is most pronounced. The rate of expansion of these activated NK cells in the first 24 hours indicates treatment success or failure. These findings suggest that strategies to improve early NK cell migration to the liver during treatment may lead to better treatment outcomes.

Disclosure of Interest None Declared